Abbott Sews Up Puncture Seal Deal As Perclose Stock Falls On Recall Rumors
This article was originally published in The Gray Sheet
Executive Summary
Abbott's July 8 acquisition of Perclose in a stock swap valued at about $680 mil. portends the firm's long-term strategy to expand its interventional cardiology presence at a tempered pace.